The novel coronavirus 2019 (COVID-19) has caused a serious global pandemic in just eight months. Nearly every country and territory in the world has been affected by the virus. The virulence and infection rate of the virus are profound, and has required extreme social distancing measures across the globe in order to prevent overwhelming the healthcare services and hospitals. COVID-19 appears to have the greatest effects on elderly individuals and those who have co-morbid diseases, such as heart disease, asthma, and diabetes. As the peak begins to slow in many countries, the death rates remain high amidst justified fears of a second wave. A rapid worldwide mobilization has begun to identify effective treatments and develop vaccines. This new volume will increase readers’ understanding of the ongoing COVID-19 pandemic through a series of chapters that address these concerns. Leading experts will discuss the effects of the virus in cases of co-morbidities, new treatment approaches, mental health aspects of the pandemic, and convey the results of survey studies. The book will be an excellent resource for researchers studying virology, metabolic diseases, respiratory disorders, and clinical scientists, physicians, drug companies, and healthcare services and workers.

Coronavirus Drug Discovery, Volume Three: Druggable Targets and In Silico Update presents comprehensive information on drug discovery against COVID-19. Chapters in Part One of this volume describe the various druggable targets and associated signaling pathways for effective targeting of SARS-CoV-2. In Part Two, chapters discuss the various computational approaches and in silico studies against SARS-CoV-2. Written by global team of experts, this book is an excellent resource that will be extremely useful to drug developers, medicinal chemists, pharmaceutical companies in R&D, research institutes in both academia and industry, and the National Library of Medicines and Health. In addition, agencies such as the National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, European Medicines Agency, the US Food and Drug Administration, and all others involved in drug discovery against COVID-19 will find this book useful. Discusses the pathogenic mechanisms of SARS-CoV-2 and druggable targets Reviews the various signaling pathways associated with SAR-CoV-2 as possible druggable targets Presents computational approaches and in silico studies against SARS-CoV-2

This book focus on COVID-19 topics, with emphasis on metabolomics and diagnosis. The chapters cover the chemical science for prevention and understanding outbreaks of infectious diseases. This book compiles the most widespread methodologies of application of quality statistical tools added to the evaluation of diagnostic tests for detection of SARS-CoV-2, metabolic behavior of COVID infection severity, and trends in rapid test for COVID-19.

Coronavirus Drug Discovery, Volume 1: SARS-CoV-2 (COVID-19) Prevention, Diagnosis, and Treatment is the first of three volumes presenting comprehensive information on drug discovery against COVID-19. This volume provides background information on the genesis of COVID-19, the epidemiology, transmission, pathogenesis, and mutagenesis. It also presents the various treatment options, drug discovery opportunities and vaccine developmental processes. Written by global team of experts from key institutions across the globe, this book is recommended to all concerned agencies, private research firms, and consortiums working on finding a solution to COVID-19 and its variants. By design, this book will be useful to drug developers, medicinal chemists, pharmacologists, health experts, researchers, students and faculty members in industry and academia. Presents information on the genesis of COVID-19, global impact and collaborative efforts Details the epidemiology, transmission, pathogenesis, and mutagenesis of SARS-CoV-2 Documents the various treatment options and vaccine development for COVID-19

This book describes the development of novel protein–RNA-binding assays and their applications in a high-throughput manner for the identification of small-molecule modulators of protein–RNA interactions to treat cancer and COVID-19. Modulating protein–RNA interactions with small molecules is expected to provide novel biological insights of the interrelation of diseases with the protein–RNA interactome. The modulations may also be exploited therapeutically. For these reasons, the development of a simple, reliable, and sensitive protein–RNA-binding assay is necessary for high-throughput screening to discover new effective chemical entities capable of acting on diverse protein–RNA interactions. This book discusses the discovery of small-molecule modulators targeting protein–RNA interactions that are potentially valuable to treat cancer and COVID-19 by constructing novel high-throughput screening methods. The results of this dissertation provide valuable insights into the regulation of protein–RNA interactions in chemical biology and drug development.

This essential volume explores a variety of tools and protocols of structure-based (homology modeling, molecular docking, molecular dynamics, protein-protein interaction network) and ligand-based (pharmacophore mapping, quantitative structure-activity relationships or QSARs) drug design for ranking and prioritization of candidate molecules in search of effective treatment strategy against coronaviruses. Beginning with an introductory section that discusses coronavirus interactions with humanity and COVID-19 in particular, the book then continues with sections on tools and methodologies, literature reports and case studies, as well as online tools and databases that can be used for computational anti-coronavirus drug research. Written for the Methods in Pharmacology and Toxicology series, chapters include the kind of practical detail and implementation advice that ensures high quality results in the lab. Comprehensive and timely, In Silico Modeling of Drugs Against Coronaviruses: Computational Tools and Protocols is an ideal reference for researchers working on the development of novel anti-coronavirus drugs for SARS-CoV-2 and for coronaviruses that will likely appear in the future.